IL31RA
Interleukin-31 receptor subunit alpha
As of the edition of 20 October 2026, IL31RA (interleukin-31 receptor subunit alpha, UniProt Q8NI17) has 1 drug tested at it and 5 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q8NI17
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- In more than one place
- Solved structures
- 2
- Disease areas
- Skin and connective tissue; Immune system; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive; Lungs and airways
- Registered trials of its drugs
- 26
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Nemolizumab | Marketed | Phase 4 | Ends 2036 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 3 |
| Total on the list | 5 |
The other 3 companies at IL31RA
In the product5 companies in all; 3 are not named here, and no score is.
See the 5 companies at IL31RA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.